Sales & Earnings

Krka insisted that its margins were “stable and high,” as the Slovenian firm reported another solid quarter.

Teva enjoyed a favorable tax status for years in its domestic Israel. However, after the firm battled in court against challenges to its historic tax payments, Teva has now agreed a three-quarters-of-a-billion dollar settlement agreement with the Israel Tax Authority.

Alvotech has announced its latest European biosimilars partnership, collaborating with Advanz on both 2mg and 8mg aflibercept rivals to Eylea. The deal follows several other recent alliances as well as a raise in Alvotech’s full-year revenues guidance to as much as $500m.

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

Alkem has missed analyst estimates with its fourth quarter revenue results, which featured a domestic slump in the anti-infective segment, despite higher EBITDA margins.

While Eugia continues to look for ways to solve the future challenges amidst temporary plant closure, parent Aurobindo reported a “good” performance in FY2024, with expected continued growth, and gave an update on its Auro Peptides business and GLP-1s.

India’s Torrent underlined that it had no plans of decreasing its commitment to the US market, while plotting continued growth in India and Germany, as it delivered financial results for its 2023/24 financial year.

Sun Pharma will finally merge with Taro as a single company, after failed attempts to absorb the firm over a decade ago. Also, the firm hints about its upcoming generic portfolio, including GLP-1 products, as well as increasing investment into its specialty business.

Eagle Pharmaceuticals has responded to the Nasdaq’s threat to delist its securities from the stock exchange after racking up a number of overdue financial documents. Generics Bulletin delves into the ongoing saga.

Krka has reaffirmed its full-year financial goals after a solid start to 2024, which included 8% revenue growth for its pharmaceutical products. Generics Bulletin examines the company’s sprawling global operations.

The American pharma reported first quarter results that highlighted the ongoing impact of shortages affecting Amphastar’s competitors, alongside the first sales of Baqsimi.

With two M&A deals expected to close in the second quarter, Gedeon Richter counts its wins and losses from a “solid” start to the year.

The Indian business crossed a major threshold as its biosimilars division earned over $1bn in revenue in the 2024 fiscal year, while also facing analyst skepticism over the performance of its other businesses.

The Japanese generics giant shared its annual results for 2023 in what was a transformative year for the company that included the sale of a subsidiary and government inspections.

While investigating the potential of the Japanese market for its denosumab, Gedeon Richter is preparing for several regulatory filings, including its tocilizumab biosimilar.

Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.